Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vociprotafib - REVOLUTION Medicine

Next Previous
Drug Profile

Vociprotafib - REVOLUTION Medicine

Alternative Names: RMC-4630; SAR 442720

Latest Information Update: 25 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator REVOLUTION Medicines
  • Developer Amgen; Netherlands Cancer Institute; REVOLUTION Medicines; Sanofi; The Lustgarten Foundation
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Protein tyrosine phosphatase non receptor type 11 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Colorectal cancer; Solid tumours
  • Phase I Pancreatic cancer

Most Recent Events

  • 23 Jan 2024 Mirati Therapeutics has been acquired by Bristol-Myers Squibb
  • 20 Oct 2023 Pharmacokinetics, efficacy and adverse events data from the phase I/Ib SHERPA trial presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 27 Feb 2023 REVOLUTION Medicine plans to evaluate RMC-4630 in combination with its RAS(ON) Inhibitors in the future
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top